Prime Highlight 

• Mursla Bio has partnered with a leading global pharmaceutical company to accelerate biomarker-guided drug development for metabolic dysfunction-associated steatohepatitis (MASH) using its AI Precision Medicine Platform. 

• The collaboration aims to identify patients most likely to respond to investigational therapies and strengthen Mursla Bio’s AI models for liver disease. 

Key Facts 

• The project will generate detailed mRNA and protein datasets from hepatocyte-specific extracellular vesicles (h-EVs) collected from MASH patients and healthy volunteers. 

• MASH affects 5–7% of adults globally and is linked to obesity and type 2 diabetes, potentially leading to cirrhosis, liver failure, or liver cancer. 

Background 

Mursla Bio has entered a new collaboration with a leading global pharmaceutical company to accelerate biomarker-guided drug development for metabolic dysfunction-associated steatohepatitis (MASH). The partnership will use Mursla Bio’s AI Precision Medicine Platform to analyse hepatocyte-specific extracellular vesicles (h-EVs) collected from MASH patients and matched healthy volunteers.

In the first phase, the partners will create detailed mRNA and protein datasets from h-EVs. These datasets will help researchers study liver tissue in MASH, find important pathways, and group patients more effectively for treatment. The findings will also strengthen Mursla Bio’s existing AI models for liver disease, developed through the company’s MEV01 clinical study.

Mursla Bio said the collaboration will explore biomarker panels that can identify patients most likely to respond to the pharmaceutical company’s investigational therapy. The same technology framework used for the company’s lead product, EvoLiver, which received FDA Breakthrough Device Designation, will be applied to advance these biomarkers into potential companion diagnostics.

Pierre Arsène, Founder and CEO of Mursla Bio, said the agreement reflects rising demand from global drug developers for precise, liver-specific biomarkers. He noted that as GLP-1 therapies reshape obesity care, MASH is becoming a major therapeutic priority. “By profiling intact hepatocyte biology inside h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care,” he said.

The partnership expands Mursla Bio’s work in hepatology and builds on the momentum created by EvoLiver’s regulatory progress.

MASH, a progressive form of fatty liver disease linked to obesity and type 2 diabetes, affects 5–7% of adults globally and can lead to cirrhosis, liver failure, or liver cancer.